201 related articles for article (PubMed ID: 27109624)
21. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
22. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
23. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.
Ray LA; Bujarski S; Squeglia LM; Ashenhurst JR; Anton RF
Alcohol Alcohol; 2014; 49(3):261-70. PubMed ID: 24421289
[TBL] [Abstract][Full Text] [Related]
24. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.
Chamberlain SR; Mogg K; Bradley BP; Koch A; Dodds CM; Tao WX; Maltby K; Sarai B; Napolitano A; Richards DB; Bullmore ET; Nathan PJ
Psychopharmacology (Berl); 2012 Dec; 224(4):501-9. PubMed ID: 22752384
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
26. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype.
Setiawan E; Pihl RO; Cox SM; Gianoulakis C; Palmour RM; Benkelfat C; Leyton M
Alcohol Clin Exp Res; 2011 Jun; 35(6):1134-41. PubMed ID: 21410481
[TBL] [Abstract][Full Text] [Related]
27. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
[TBL] [Abstract][Full Text] [Related]
28. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.
Ashenhurst JR; Bujarski S; Ray LA
Pharmacol Biochem Behav; 2012 Dec; 103(2):253-9. PubMed ID: 22954510
[TBL] [Abstract][Full Text] [Related]
29. Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism.
Browne CA; Erickson RL; Blendy JA; Lucki I
Neuropharmacology; 2017 May; 117():401-407. PubMed ID: 28188737
[TBL] [Abstract][Full Text] [Related]
30. Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.
Peciña M; Love T; Stohler CS; Goldman D; Zubieta JK
Neuropsychopharmacology; 2015 Mar; 40(4):957-65. PubMed ID: 25308352
[TBL] [Abstract][Full Text] [Related]
31. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.
Vallender EJ; Rüedi-Bettschen D; Miller GM; Platt DM
Drug Alcohol Depend; 2010 Jun; 109(1-3):252-6. PubMed ID: 20153935
[TBL] [Abstract][Full Text] [Related]
32. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine.
Ray R; Jepson C; Patterson F; Strasser A; Rukstalis M; Perkins K; Lynch KG; O'Malley S; Berrettini WH; Lerman C
Psychopharmacology (Berl); 2006 Oct; 188(3):355-63. PubMed ID: 16960700
[TBL] [Abstract][Full Text] [Related]
33. A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice.
Bilbao A; Robinson JE; Heilig M; Malanga CJ; Spanagel R; Sommer WH; Thorsell A
Biol Psychiatry; 2015 May; 77(10):850-8. PubMed ID: 25442002
[TBL] [Abstract][Full Text] [Related]
34. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
Barr CS; Chen SA; Schwandt ML; Lindell SG; Sun H; Suomi SJ; Heilig M
Biol Psychiatry; 2010 Jan; 67(1):78-80. PubMed ID: 19748082
[TBL] [Abstract][Full Text] [Related]
35. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
[TBL] [Abstract][Full Text] [Related]
36. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.
Weerts EM; Wand GS; Maher B; Xu X; Stephens MA; Yang X; McCaul ME
Alcohol Clin Exp Res; 2017 Jun; 41(6):1093-1104. PubMed ID: 28376280
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
38. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
39. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
Setiawan E; Pihl RO; Benkelfat C; Leyton M
Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
[TBL] [Abstract][Full Text] [Related]
40. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
Lim AC; Ghahremani DG; Grodin EN; Green R; Bujarski S; Hartwell EE; Courtney KE; Hutchison K; Miotto K; Ray LA
Drug Alcohol Depend; 2019 Jul; 200():181-190. PubMed ID: 31160146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
